Researches

South Egypt Cancer Institute

Assiut University

# Title Department Research Member Research Year
1 Analysis of chest wall breathing motion, setup accuracy and dosimetric stability of VMAT technique radiation therapy in breast cancer patients Department of Radiotherapy and Nuclear medicine Dr. Shaimaa / Elsayyed Youssef / Ahmed July 2021
2 Evaluation of Safety and Efficacy of 1 week versus 3 weeks hypofractionation radiotherapy for breast cancer patients: Phase III trial Department of Radiotherapy and Nuclear medicine Dr. Shaimaa / Elsayyed Youssef / Ahmed January2023(1):
3 Beta Endorphins, Interleukin 1 and Interleukin 38 in Covid Patients Associated with Neuropsychological Manifestations Department of Clinical Pathology Dr. Engy adel shafeek 2024
4 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Prof. Ashraf Zeidan Abdalla Ahmed 2024
5 Assessment of Response to Hormonal Therapy by Serum Ki-67 as a Biomarker in Non-metastatic Hormone Positive Breast Cancer Department of Medical Oncology Zeina Omar Attia Sayed 2024
6 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Shimaa Hassan Shabaan Hassan 2024
7 Factors affecting timing of hypothyroidism following radioactive iodine therapy (RAIT) for patients with Graves' disease: A 12-month observational study Department of Radiotherapy and Nuclear medicine Dr. Esraa Roshdy Hassan Mohamed 2024
8 Role of Irreversible Electroporation in Solid Abdominal Tumors Management Department of Radiology Dr. Doaa Mohamed Fouad Mahmoud 2024
9 Factors affecting timing of hypothyroidism following radioactive iodine therapy (RAIT) for patients with Graves' disease: A 12-month observational study Department of Radiotherapy and Nuclear medicine ِAya AbdelBaset Ahmed 2024
10 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Amen Hamdy Zaki Ali 2024